📰 Advanced Solid Tumors News
Page 7 - Advanced Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.
September 10, 2022
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of...
September 10, 2022
10.09.2022 - - Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to report results of ADG126 dose escalation in combination ... Seite 1
September 10, 2022
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors GlobeNewswire September 10, 2022 - Best-in-class profile demonstrated with repeat dosing across dose levels - The poster, titled “Phase 1 Results Demonstrate Highly Differentiated Safety and PK...
September 7, 2022
Not intended for US- or Canada-based media Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unresected
May 26, 2022
/PRNewswire/ -- Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug...
May 26, 2022
/PRNewswire/ -- Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug...
May 11, 2022
-- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity) ...
May 10, 2022
Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-1 Refractory Disease ... | May 10, 2022
April 28, 2022
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. (“Rubius” or the...
April 23, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such...